How many clinical-trial readouts are scheduled for October 2027?

pdufa.bio currently tracks 26 clinical-trial readouts with dates in October 2027, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › Readouts › October 2027

October 2027 clinical-trial readouts

trial-readout estimates for October 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← September 2027 November 2027 →

26 readouts

CERS · Oct 2027 (est.)

S-303 Treated Red Blood Cells — Transfusion Reaction, Hemolytic

CLYM · Oct 2027 (est.)

Budoprutug — Primary Membranous Nephropathy

CORT · Oct 2027 (est.)

Relacorilant — Metastatic Breast Cancer

EVMN · Oct 2027 (est.)

EVO756 — Migraine

EYPT · Oct 2027 (est.)

EYP-1901 — Diabetic Macular Edema

ICLR · Oct 2027 (est.)

PRX-102 — Fabry Disease

JBIO · Oct 2027 (est.)

JADE101 — Rhematoid Arthritis

LLY · Oct 2027 (est.)

Tirzepatide — Obesity

NBIX · Oct 2027 (est.)

NBI-1065845 — Schizophrenia

NVCR · Oct 2027 (est.)

Temozolomide — Pancreas Cancer

OGN · Oct 2027 (est.)

150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5 — Esophagogastric Adenocarcinoma

ONC · Oct 2027 (est.)

Zanubrutinib — Primary Membranous Nephropathy

OPK · Oct 2027 (est.)

CTAP101 — CKD Stage 3

ORKA · Oct 2027 (est.)

ORKA-001 — Plaque Psoriasis

TARS · Oct 2027 (est.)

TP-03 — Lyme Disease

VERU · Oct 2027 (est.)

Enobosarm & Abemaciclib Combo — Obesity & Overweight

AGEN · Oct 2027 (est.)

Balstilimab — Metastatic Prostate Cancer

APVO · Oct 2027 (est.)

ALG.APV-527 — Acute Myeloid Leukemia (AML)

MRK · Oct 2027 (est.)

MK-8527 — Human Immunodeficiency Virus (HIV)

ONC · Oct 2027 (est.)

Tislelizumab — Metastatic Gastric Adenocarcinoma

PBYI · Oct 2027 (est.)

neratinib — Small Cell Lung Cancer

RYTM · Oct 2027 (est.)

Setmelanotide — Obesity Associated With Defects in Leptin-melanocortin Pathway

TFX · Oct 2027 (est.)

Fresh Frozen Plasma — Cervix Cancer

TLX · Oct 2027 (est.)

177Lu-TLX591 — Advanced Cancer

CUE · Oct 2027 (est.)

CUE-101 — Oropharyngeal Squamous Cell Carcinoma

LXRX · Oct 2027 (est.)

Sotagliflozin — Type 1 Diabetes

Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).